α2-adrenoceptor antagonism is neither sufficient nor necessary for the distinctive action of atypical neuroleptics on intracranial self-stimulation in the rat

Behavioural Pharmacology

Volumn 14, Issue 4, 2003, Pages 307-314

  Montgomery, A M J ^a,d   Grottick, A J ^a,b   Herberg, L J ^c  

^a LONDON METROPOLITAN UNIVERSITY   (United Kingdom)

^b ARENA PHARMACEUTICALS   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF GREENWICH   (United Kingdom)

Author keywords

Atypical neuroleptics; Clonidine; Haloperidol; Idazoxan; Olanzapine; Rat; Schizophrenia; Self stimulation; Typical neuroleptics; 2 adrenoceptors

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CLONIDINE; HALOPERIDOL; IDAZOXAN; OLANZAPINE;

ANIMAL BEHAVIOR; ARTICLE; BRAIN FUNCTION; CONTROLLED STUDY; DEPRESSION; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELF ADMINISTRATION; MALE; NONHUMAN; PSYCHOPHARMACOTHERAPY; RAT; RECEPTOR AFFINITY; SCHIZOPHRENIA; SELF STIMULATION; VENTRAL TEGMENTUM;

EID: 0042868855     PISSN: 09558810     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.fbp.0000080415.40539.b9     Document Type: Article

References (27)

1. Aravagiri M, Teper Y, Marder SR (1999). Pharmacokinetics and tissue distribution of olanzapine in rats. Biopharm Drug Dispos 20:369-377.
2. Bartholini G (1977). Preferential effect of noncataleptogenic neuroleptics on mesolimbic function. Adv Biochem Psychopharmacol 16:607-611.
3. Beasley CM Jr, Hamilton SH, Crawford AM, Dellva MA, Tollefson GD, Tran PV, et al. (1997). Olanzapine versus haloperidol: acute phase results of the international double-blind trial. Eur Neuropsychopharmacol 7:125-137.
4. Bymaster FP, Calligaro DO, Falcone JF, Marsh RD, Moore NA, Tye NC, et al. (1996). Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87-96.
5. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM (1999). Olanzapine, pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet 37:177-193.
6. Egan CT, Herrick-Davis K, Teitler M (1998). Creation of a constitutively activated state of the 5-hydroxytryptamine2A receptor by site-directed mutagenesis: inverse agonist activity of antipsychotic drugs. J Pharmacol Exp Ther 286:85-90.
7. Fouriezos G, Wise RA (1976). Pimozide-induced extinction of intracranial self-stimulation: Response patterns rule out motor or performance deficits. Brain Res 103:377-380.
8. 2 receptor stimulation. Pharmacol Biochem Behav 58:1045-1049.
9. 2-Adrenoceptor antagonism may contribute to the atypical properties of risperidone: Experimental support for the Nutt case. J Psychopharmacol 9:281-283.
10. Kane J, Honigfeld G, Singer J, Meltzer HY (1988). Clozapine for the treatment-resistant schizophrenic: A double blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796.
11. Kapur S, Seeman P (2000). Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci 25:161-166.
12. Kapur S, Seeman P (2001). Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 158:360-369.
13. 2 receptors. Psychopharmacology 112:S40-S54.
14. Mattiuz E, Franklin R, Gillespie T, Murphey A, Bernstein J, Chiu A et al. (1997). Disposition and metabolism of olanzapine in mice, dogs and rhesus monkeys. Drug Metab Dispos 25:573-583.
15. Meltzer HY (1992). The importance of serotonin dopamine interactions in the action of clozapine. Br J Psychiatry 160:22-29.
16. 2-adrenoceptor agonist, clonidine. Behav Pharmacol 10:475-482.
17. 2-adrenoceptor antagonism account for the therapeutic advantage of new antipsyohotics?. J Psychopharmacol 9:155.
18. Moore NA, Tye NC, Axton MS, Risius FC (1992). The behavioural pharmacology of olanzapine, a novel 'atypical' antipsychotic agent. J Pharmacol Exp Ther 262:545-551.
19. 2-adrenoceptor antagonism account for the therapeutic advantage of new antipsychotics?. J Psychopharmacol 8:193-195.
20. Paxinos G, Watson C (1986). The Rat Brain in Stereotaxic Co-ordinates. 2nd ed. Sydney: Academic Press.
21. Sanger DJ (1986). Response decrement patterns after neuroleptic and non-neuroleptic drugs. Psychopharmacology 89:98-104.
22. Schultz SK, Andreasen NC (1999). Schizophrenia. Lancet 353:1425-1430.
23. Song F (1997). Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials. J Psychopharmacol 11:65-71.
24. Stephens DN, Löschmann PA, Lanzinger I, Wachtel H, Montgomery AMJ, Herberg LJ (1990). Unusual interactions between the neuroleptic haloperidol and the D2 partial agonist, terguride. Behav Pharmacol 1:521-529.
25. Sumiyoshi T, Kido H, Sakamoto H, et al. (1994). In vivo dopamine-D2 and serotonin-5-HT2 receptor binding study of risperidone and haloperidol. Pharmacol Biochem Behav 47:553-557.
26. Tran PV, Dellva MA, Tollefson GD, Beasley CM Jr, Potvin JH, Kiesler GM (1997). Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 58:205-211.
27. Wauquier A (1976). The influence of psychoactive drugs on brain self-stimulation in rats: a review. In: Wauquier A, Rolls ET (editors): Brain Stimulation Reward. Amsterdam: North Holland; pp. 127-170.